Welcome!

News Feed Item

Spina Bifida Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Spina Bifida Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280944/Spina-Bifida-Global-Clinical-Trials-Review-H2-2014.html

Spina Bifida Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Spina Bifida Global Clinical Trials Review, H2, 2014" provides data on the Spina Bifida clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Spina Bifida. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Spina Bifida. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Spina Bifida 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Central and South America 12
Clinical Trials by G7 Countries: Proportion of Spina Bifida to Central Nervous System Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Spina Bifida to Central Nervous System Clinical Trials 16
Clinical Trials by Phase 17
In Progress Trials by Phase 18
Clinical Trials by Trial Status 19
Clinical Trials by End Point Status 20
Unaccomplished Trials of Spina Bifida 21
Subjects Recruited Over a Period of Time 22
Clinical Trials by Sponsor Type 23
Prominent Sponsors 24
Prominent Drugs 25
Clinical Trial Profiles 26
Clinical Trial Overview of Top Companies 26
Tengion, Inc. 26
Clinical Trial Overview of Tengion, Inc. 26
Clinical Trial Overview of Top Institutes / Government 27
Eunice Kennedy Shriver National Institute of Child Health and Human Development 27
Clinical Trial Overview of Eunice Kennedy Shriver National Institute of Child Health and Human Development 27
Centers for Disease Control and Prevention 28
Clinical Trial Overview of Centers for Disease Control and Prevention 28
William Beaumont Hospitals 29
Clinical Trial Overview of William Beaumont Hospitals 29
Aarhus University 30
Clinical Trial Overview of Aarhus University 30
Rennes University Hospital 31
Clinical Trial Overview of Rennes University Hospital 31
Baylor College of Medicine 32
Clinical Trial Overview of Baylor College of Medicine 32
UMC Utrecht Holding BV 33
Clinical Trial Overview of UMC Utrecht Holding BV 33
Universitaire Ziekenhuizen Leuven 34
Clinical Trial Overview of Universitaire Ziekenhuizen Leuven 34
University of New Mexico 35
Clinical Trial Overview of University of New Mexico 35
Duke University 36
Clinical Trial Overview of Duke University 36
Five Key Clinical Profiles 37
Appendix 56
Abbreviations 56
Definitions 56
Research Methodology 57
Secondary Research 57
About GlobalData 58
Contact Us 58
Disclaimer 58
Source 58

List of Tables

Spina Bifida Therapeutics, Global, Clinical Trials by Region, 2014* 6
Spina Bifida Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Spina Bifida Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Spina Bifida Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 9
Spina Bifida Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 10
Spina Bifida Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Spina Bifida Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 12
Proportion of Spina Bifida to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Spina Bifida Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Spina Bifida Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Spina Bifida to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Spina Bifida Therapeutics, Global, Clinical Trials by Phase, 2014* 17
Spina Bifida Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 18
Spina Bifida Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Spina Bifida Therapeutics Clinical Trials, Global, by End Point Status, 2014* 20
Spina Bifida Therapeutics, Global, Withdrawn Clinical Trials, 2014* 21
Spina Bifida Therapeutics, Global, Terminated Clinical Trials, 2014* 21
Spina Bifida Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Spina Bifida Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 23
Spina Bifida Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 24
Spina Bifida Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 25
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Tengion, Inc., 2014* 26
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Eunice Kennedy Shriver National Institute of Child Health and Human Development, 2014* 27
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Centers for Disease Control and Prevention, 2014* 28
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by William Beaumont Hospitals, 2014* 29
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Aarhus University, 2014* 30
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Rennes University Hospital, 2014* 31
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Baylor College of Medicine, 2014* 32
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by UMC Utrecht Holding BV, 2014* 33
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Universitaire Ziekenhuizen Leuven, 2014* 34
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by University of New Mexico, 2014* 35
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014* 36

List of Figures

Spina Bifida Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Spina Bifida Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Spina Bifida Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Spina Bifida Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 10
Proportion of Spina Bifida to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Spina Bifida Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Spina Bifida Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Spina Bifida to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Spina Bifida Therapeutics, Global, Clinical Trials by Phase (%), 2014* 17
Spina Bifida Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 18
Spina Bifida Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Spina Bifida Therapeutics Clinical Trials, Global, by End Point Status, 2014* 20
Spina Bifida Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Spina Bifida Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 23
GlobalData Methodology 57

To order this report: Spina Bifida Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280944/Spina-Bifida-Global-Clinical-Trials-Review-H2-2014.html

__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
DX World EXPO, LLC, a Lighthouse Point, Florida-based startup trade show producer and the creator of "DXWorldEXPO® - Digital Transformation Conference & Expo" has announced its executive management team. The team is headed by Levent Selamoglu, who has been named CEO. "Now is the time for a truly global DX event, to bring together the leading minds from the technology world in a conversation about Digital Transformation," he said in making the announcement.
"Space Monkey by Vivent Smart Home is a product that is a distributed cloud-based edge storage network. Vivent Smart Home, our parent company, is a smart home provider that places a lot of hard drives across homes in North America," explained JT Olds, Director of Engineering, and Brandon Crowfeather, Product Manager, at Vivint Smart Home, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today that Conference Guru has been named “Media Sponsor” of the 22nd International Cloud Expo, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. A valuable conference experience generates new contacts, sales leads, potential strategic partners and potential investors; helps gather competitive intelligence and even provides inspiration for new products and services. Conference Guru works with conference organizers to pass great deals to gre...
DevOps is under attack because developers don’t want to mess with infrastructure. They will happily own their code into production, but want to use platforms instead of raw automation. That’s changing the landscape that we understand as DevOps with both architecture concepts (CloudNative) and process redefinition (SRE). Rob Hirschfeld’s recent work in Kubernetes operations has led to the conclusion that containers and related platforms have changed the way we should be thinking about DevOps and...
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and shared the must-have mindsets for removing complexity from the develop...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering m...
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous ar...
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
"Evatronix provides design services to companies that need to integrate the IoT technology in their products but they don't necessarily have the expertise, knowledge and design team to do so," explained Adam Morawiec, VP of Business Development at Evatronix, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. In his session at @BigDataExpo, Jack Norris, Senior Vice President, Data and Applications at MapR Technologies, reviewed best practices to ...
Widespread fragmentation is stalling the growth of the IIoT and making it difficult for partners to work together. The number of software platforms, apps, hardware and connectivity standards is creating paralysis among businesses that are afraid of being locked into a solution. EdgeX Foundry is unifying the community around a common IoT edge framework and an ecosystem of interoperable components.
"ZeroStack is a startup in Silicon Valley. We're solving a very interesting problem around bringing public cloud convenience with private cloud control for enterprises and mid-size companies," explained Kamesh Pemmaraju, VP of Product Management at ZeroStack, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Large industrial manufacturing organizations are adopting the agile principles of cloud software companies. The industrial manufacturing development process has not scaled over time. Now that design CAD teams are geographically distributed, centralizing their work is key. With large multi-gigabyte projects, outdated tools have stifled industrial team agility, time-to-market milestones, and impacted P&L stakeholders.
"Akvelon is a software development company and we also provide consultancy services to folks who are looking to scale or accelerate their engineering roadmaps," explained Jeremiah Mothersell, Marketing Manager at Akvelon, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Enterprises are adopting Kubernetes to accelerate the development and the delivery of cloud-native applications. However, sharing a Kubernetes cluster between members of the same team can be challenging. And, sharing clusters across multiple teams is even harder. Kubernetes offers several constructs to help implement segmentation and isolation. However, these primitives can be complex to understand and apply. As a result, it’s becoming common for enterprises to end up with several clusters. Thi...